BRPI0311176B8 - pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica - Google Patents

pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica

Info

Publication number
BRPI0311176B8
BRPI0311176B8 BRPI0311176A BR0311176A BRPI0311176B8 BR PI0311176 B8 BRPI0311176 B8 BR PI0311176B8 BR PI0311176 A BRPI0311176 A BR PI0311176A BR 0311176 A BR0311176 A BR 0311176A BR PI0311176 B8 BRPI0311176 B8 BR PI0311176B8
Authority
BR
Brazil
Prior art keywords
pseudopolymorph
ethanolate
pharmaceutical composition
preparation process
pseudopolymorphic forms
Prior art date
Application number
BRPI0311176A
Other languages
English (en)
Other versions
BR0311176A (pt
BRPI0311176B1 (pt
Inventor
Joseph Christiaan Thoné Daniel
Wim Pieter Vermeersch Hans
Donné Marie-Louise Janssens Luc
Tom Bert Paul Wigerinck Piet
Original Assignee
Janssen Sciences Ireland Uc
Janssen R&D Ireland
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0311176(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc, Janssen R&D Ireland, Tibotec Pharm Ltd filed Critical Janssen Sciences Ireland Uc
Publication of BR0311176A publication Critical patent/BR0311176A/pt
Publication of BRPI0311176B1 publication Critical patent/BRPI0311176B1/pt
Publication of BRPI0311176B8 publication Critical patent/BRPI0311176B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

formas pseudopolimórficas de um inibidor da protease do hiv. a presente invenção refere-se a novas formas pseudopolimórficas de (3r,3as,6ar)-hexahidrofuro[2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato e processos para a produção das mesmas.
BRPI0311176A 2002-05-16 2003-05-16 pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica BRPI0311176B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076929.5 2002-05-16
EP02076929 2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (3)

Publication Number Publication Date
BR0311176A BR0311176A (pt) 2005-03-15
BRPI0311176B1 BRPI0311176B1 (pt) 2019-08-20
BRPI0311176B8 true BRPI0311176B8 (pt) 2021-05-25

Family

ID=29724454

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311176A BRPI0311176B8 (pt) 2002-05-16 2003-05-16 pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica

Country Status (25)

Country Link
US (8) US7700645B2 (pt)
EP (4) EP2314591B2 (pt)
JP (1) JP4864320B2 (pt)
KR (2) KR20100119906A (pt)
CN (1) CN100475819C (pt)
AP (1) AP2052A (pt)
AU (2) AU2003271740B2 (pt)
BR (1) BRPI0311176B8 (pt)
CA (1) CA2485834C (pt)
CY (3) CY1117928T1 (pt)
DK (3) DK2767539T3 (pt)
EA (1) EA007120B8 (pt)
ES (4) ES2503551T5 (pt)
HR (1) HRP20041061B1 (pt)
HU (1) HUE034389T2 (pt)
IL (1) IL165140A0 (pt)
LT (1) LT2767539T (pt)
MX (1) MXPA04011427A (pt)
NO (1) NO331477B1 (pt)
NZ (1) NZ536497A (pt)
PL (1) PL215151B1 (pt)
PT (3) PT2314591E (pt)
SI (3) SI1567529T2 (pt)
WO (1) WO2003106461A2 (pt)
ZA (1) ZA200410154B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
ES2503551T5 (es) 2002-05-16 2021-10-28 Janssen Sciences Ireland Unlimited Co Formas pseudopolimórficas de un inhibidor de la proteasa de VIH
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
RS51073B (sr) 2003-12-23 2010-10-31 Tibotec Pharmaceuticals Ltd. Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata
AU2006217922B2 (en) 2005-02-25 2012-04-05 Janssen Sciences Ireland Uc Protease inhibitor precursor synthesis
ES2359949T3 (es) * 2006-11-09 2011-05-30 Tibotec Pharmaceuticals Métodos para preparar hexhidrofuro(2,3-b)furan-3-ol.
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
US20120035142A1 (en) * 2009-01-29 2012-02-09 Mapi Pharma Limited Polymorphs of darunavir
WO2011048604A2 (en) * 2009-09-17 2011-04-28 Matrix Laboratories Limited An improved process for the preparation of darunavir
WO2011051978A2 (en) 2009-10-30 2011-05-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
ES2546866T3 (es) * 2009-12-16 2015-09-29 Hetero Research Foundation Polimorfos de darunavir
AU2010340799B2 (en) * 2010-01-05 2015-06-11 Cipla Limited Darunavir polymorph and process for preparation thereof
EP2528923B1 (en) 2010-01-28 2014-07-30 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
EP2571355B1 (en) 2010-05-20 2016-09-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
SI2729130T1 (en) 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
WO2013108105A2 (en) * 2012-01-18 2013-07-25 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
ES2848216T3 (es) * 2012-07-24 2021-08-05 Laurus Labs Ltd Un proceso para la preparación de Darunavir
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
PL3271347T3 (pl) * 2015-03-19 2022-11-21 Mycovia Pharmaceuticals, Inc. Związki przeciwgrzybicze i sposoby wytwarzania
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
US10407438B2 (en) 2016-10-27 2019-09-10 Gilead Sciences, Inc. Crystalline forms of darunavir
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
AU7669794A (en) * 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
CN1072215C (zh) * 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
WO2000029390A1 (en) 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
EP1159278B1 (en) 1999-02-12 2005-11-30 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
ES2503551T5 (es) 2002-05-16 2021-10-28 Janssen Sciences Ireland Unlimited Co Formas pseudopolimórficas de un inhibidor de la proteasa de VIH
AU2010340799B2 (en) * 2010-01-05 2015-06-11 Cipla Limited Darunavir polymorph and process for preparation thereof

Also Published As

Publication number Publication date
NO331477B1 (no) 2012-01-16
HUE034389T2 (en) 2018-02-28
NO20045409L (no) 2004-12-10
AP2052A (en) 2009-10-05
EP3045460A1 (en) 2016-07-20
EA200401503A1 (ru) 2005-06-30
CA2485834A1 (en) 2003-12-24
SI2314591T2 (sl) 2021-08-31
US20050250845A1 (en) 2005-11-10
US10858369B2 (en) 2020-12-08
US8518987B2 (en) 2013-08-27
CY1115665T1 (el) 2017-01-25
AU2003271740B2 (en) 2010-05-13
KR20100119906A (ko) 2010-11-11
EA007120B1 (ru) 2006-06-30
SI1567529T1 (sl) 2014-11-28
AP2004003191A0 (en) 2004-12-31
LT2767539T (lt) 2017-09-25
IL165140A0 (en) 2005-12-18
EP2767539A1 (en) 2014-08-20
WO2003106461A3 (en) 2004-05-13
EP2314591B1 (en) 2014-06-18
PT2767539T (pt) 2017-08-28
ES2498370T5 (es) 2021-11-24
CY1117928T1 (el) 2017-05-17
EP1567529B2 (en) 2021-02-24
EP1567529B1 (en) 2014-06-18
ES2498370T3 (es) 2014-09-24
HK1081969A1 (en) 2006-05-26
PT2314591E (pt) 2014-09-19
US20100204316A1 (en) 2010-08-12
AU2012205289A1 (en) 2012-08-09
HRP20041061A2 (en) 2006-07-31
BR0311176A (pt) 2005-03-15
CA2485834C (en) 2007-07-17
US20130303790A1 (en) 2013-11-14
SI2314591T1 (sl) 2014-11-28
DK1567529T4 (da) 2021-05-10
EP3045460B1 (en) 2019-04-17
DK1567529T3 (da) 2014-09-15
PL215151B1 (pl) 2013-10-31
EP1567529A2 (en) 2005-08-31
KR101128370B1 (ko) 2012-04-23
WO2003106461A2 (en) 2003-12-24
PL374321A1 (en) 2005-10-17
NZ536497A (en) 2006-08-31
EP2314591A1 (en) 2011-04-27
KR20050008715A (ko) 2005-01-21
DK2314591T4 (da) 2021-05-10
BRPI0311176B1 (pt) 2019-08-20
DK2767539T3 (en) 2017-09-11
EP2314591B2 (en) 2021-02-24
ES2503551T5 (es) 2021-10-28
EA007120B8 (ru) 2012-03-30
US20150336980A1 (en) 2015-11-26
US10000504B2 (en) 2018-06-19
US20210179631A1 (en) 2021-06-17
ES2638412T3 (es) 2017-10-20
DK2314591T3 (da) 2014-09-22
US7700645B2 (en) 2010-04-20
CN1668623A (zh) 2005-09-14
PT1567529E (pt) 2014-09-09
CY1119311T1 (el) 2018-02-14
JP4864320B2 (ja) 2012-02-01
HRP20041061B1 (hr) 2015-02-27
US20180312517A1 (en) 2018-11-01
AU2003271740A1 (en) 2003-12-31
EP2767539B1 (en) 2017-07-12
SI2767539T1 (sl) 2017-10-30
US20140171499A1 (en) 2014-06-19
ZA200410154B (en) 2005-12-28
ES2728735T3 (es) 2019-10-28
SI1567529T2 (sl) 2021-08-31
CN100475819C (zh) 2009-04-08
US20170260196A1 (en) 2017-09-14
JP2005533068A (ja) 2005-11-04
ES2503551T3 (es) 2014-10-07
MXPA04011427A (es) 2005-02-17

Similar Documents

Publication Publication Date Title
BR0311176A (pt) Formas pseudopolimórficas de um inibidor da protease do hiv
CY1119150T1 (el) ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ (3R,3aS,6aR) ΕΞΑΫΔΡΟ-ΦΟΥΡΟ[2,3-b]ΦΟΥΡΑΝ-3-ΟΛΗΣ
BRPI0417272A (pt) processo para a preparação de (3r, 3as, 6ar)-hexahidrofuro [2,3-b] furan-3-3il (1s, 2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato
AR118270A2 (es) PROCESO PARA LA PREPARACIÓN DEL SOLVATO ETANOLATO DE (1S,2R)-3-[[(4-AMINOFENIL)SULFONIL](ISOBUTIL)AMINO]-1-BENCIL-2-HIDROXIPROPILCARBAMATO DE (3R,3aS,6aR)-HEXAHIDROFURO[2,3-B]FURAN-3-ILO
CY1109974T1 (el) Μεθοδος για την παρασκευη εξαϋδρο-φουρο[2,3-β]φουραν-3-ολης
UY27138A1 (es) Composiciones farmacéuticas, formas de dosificación y métodos para la administración oral de epotilonas.
HUP0400333A2 (hu) Kristályos antikolinergikum, eljárás előállítására és alkalmazása gyógyszerkészítmény előállítására
MA30000B1 (fr) Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole
MX2018004605A (es) Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
BR112012018862A2 (pt) processo para a preparação de darunavir e intermediários de darunavir
TWD189375S (zh) 汽車用頭燈
BR0311612A (pt) Catalisador orgânico com solubilidade elevada, composição e aditivo de limpeza contendo o mesmo, processo de fabricação do mesmo, processo para a produção de sulfatos cìclicos e processo de limpeza de superfìcies ou tecidos
AR037654A1 (es) Base libre de clindamicina sustancialmente cristalina, sustancia droga, composicion farmaceutica y su uso en la fabricacion de un medicamento y proceso para preparar dicha base libre cristalina de clindamicina
CY1109891T1 (el) Παραγωγα ν-(αρυλαλκυλ)-1η-πυρρολοπυριδιν-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες
BRPI0405415A (pt) Pneu otr com baixa relação entre lìquido e bruto
UY27413A1 (es) Agonistas de la oxitocina
WO2011051978A3 (en) A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
AR019477A1 (es) Triazolopiridinas para el tratamiento de los trastornos de la trombosis
EP3313847A4 (en) PROCESS FOR THE PREPARATION OF [(S 1,2R) -3 - [[(4-AMINOPHENYL) SULFONYL] (2-METHYLPROPYL) AMINO] -2-HYDROXY-1- (PHENYLMETHYL) PROPYL] -carbamic Acid (3R, 3AS, 6AR ) HEXAHYDRO-FURO [2,3-B] FURAN-3-YL ESTER AND ITS AMORPH FORM
CL2025000550A1 (es) Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
BR0214068A (pt) Preparação de derivados 3,3a,8,12b-tetrahidro-2h-dibenzo [3,4:6,7]ciclohepta[1,2-b] furano transfundidos
BR0214775A (pt) Preparação de derivados de 3,3a,8,12b-tetraidro-2h-dibenzo[3,4:6,7]ciclohepta[1,2- b]furano cis-fundidos
MX386897B (es) Procedimiento simplificado para la preparacion de darunavir
CY1115086T1 (el) Αναλογα καρβα-νουκλεοζιτων για αντιϊικη αγωγη
ES2078191B1 (es) Boquilla para instrumentos musicales de viento.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 493/04, A61P 31/00

Ipc: C07D 493/04 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.003778/2023-46 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1014637-50.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: JANSSEN SCIENCES IRELAND UC REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.003778/2023-46 SECAO JUDICIARIA DO DISTRITO FEDERAL PROCESSO JUDICIAL: 1014637-50.2023.4.01.3400 AUTOR: JANSSEN SCIENCES IRELAND UC REUS: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E OUTROS SENTENCA: PUBLICAR QUE O PRAZO DE VIGENCIA DA PATENTE OBJETO DESTA ACAO - PI0311176- 8 - ESTA SUB JUDICE, TANTO NA REVISTA DE PROPRIEDADE INDUSTRIAL, QUANTO NO STATUS DA RESPECTIVA PATENTE NO SITIO DO INPI NA INTERNET (ART. 59, INCISO II, 60 E 226 DA LPI.